Organisation paid for research Program year 2025 Source: CMS Open Payments

Wrmsra LLC

Neither a doctor nor a teaching hospital

Research payments

$1,083,584

156 payments

Through program year 2025, Wrmsra LLC is reported as receiving $1,083,584 in research payments, across 156 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$76,332	43
2024	Research	$336,418	36
2023	Research	$394,125	60
2022	Research	$276,709	17

Breakdown

Who paid Research payments · program years 2022–2025

Pfizer Inc. $1,028,573 111 payments
Biohaven Pharmaceutical Holding Company Ltd. $55,011 45 payments

Studies the money was for Research payments · program years 2022–2025

A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $634,546 38 payments
A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $305,245 25 payments
A Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Infectious Respiratory Illnesses Including Covid19 and RSV in Healthy Individuals $67,595 9 payments
A Phase 4 Randomized Doubleblind Placebocontrolled Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use $44,041 65 payments
An Interventional Phase 23 Adaptive Multicenter Randomized Doubleblind Study to Investigate Efficacy and Safety of Oral Sisunatovir Compared With Placebo in Nonhospitalized Symptomatic Adults With Respiratory Syncytial Virus Infection Who Are at Risk of Progression to Severe Illness $17,450 4 payments
A Phase 4 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With A History of Inadequate Response to Oral Preventive Medications $12,575 8 payments
A Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Infectious Respiratory Illnesses Including Covid19 and RSV in Healthy Individuals $1,946 2 payments
A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $186 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.